<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151017</url>
  </required_header>
  <id_info>
    <org_study_id>20170467</org_study_id>
    <nct_id>NCT04151017</nct_id>
  </id_info>
  <brief_title>Efficacy of Autologous Fibrin Glue in Pterygium</brief_title>
  <official_title>Efficacy of Autologous Fibrin Glue Versus Suture for Conjuntival Autografting in Primary Pterygium Surgery: a Randomized Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pterygium is wing-shaped, vascular, fleshy growth that originates on the conjuntiva and that
      can spread to the corneal limbus and beyond The surgical exeresis with autologous
      conjunctival autograft technique is the treatment of choice. Commercially available fibrin
      glue has been used preferentially for graft fixation due to its benefits compared to sutures;
      However, its cost and the risk of inflammatory immune reaction limit the its use. There are
      few studies about autologous fibrin glue.

      OBJECTIVE: To determine the efficacy of autologous fibrin glue preparation in patients
      undergoing pterygium resection surgery. To compare with autologous conjunctival graft
      fixation with suture.

      This is a randomized clinical trial. Two patient groups will undergo pterygium excision
      surgery. Group 1 will have autologous conjunctival graft fixation with autologous fibrin glue
      and group 2 will have suture graft fixation using 10.0 mononylon. Early and late
      postoperative surgical results as well as complication rates will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence in 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autograft Retraction</measure>
    <time_frame>30 days</time_frame>
    <description>Graft detachment from one or more sides but still in place</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence Pain</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Presence Pain measured by a five-point scale, in which 0 means absence of symptom; 1 means easily tolerable symptom; 2 means symptom causing some discomfort; 3 means symptom partially interfering with usual activities and 4 means symptom completely interfering with usual activities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>Autologous fibrin glue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sutures</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous fibrin glue</intervention_name>
    <description>Conjunctival graft fixation with autologous fibrin glue</description>
    <arm_group_label>Autologous fibrin glue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Suture</intervention_name>
    <description>Graft fixation using 10.0 mononylon</description>
    <arm_group_label>Sutures</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nasal primary pterygium

        Exclusion Criteria:

          -  relapsed pterygium

          -  patients with a history of previous eye surgery

          -  patients with glaucoma using hypotensive eye drops

          -  eye surface diseases

          -  eye allergy

          -  diabetic patients,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Marinho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Cioba</last_name>
    <phone>5551 32148000</phone>
    <email>christinecioba@yahoo.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Cioba</last_name>
      <phone>555132148000</phone>
      <email>christinecioba@yahoo.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

